Detail akcie Fulgent Genetics online

Business Summary: Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Fulgent Genetics Inc revenues increased 15% to $239.3M. Net loss increased 1% to $37.1M. Revenues reflect Institutional segment increase from $39.8M to $125.3M, Insurance segment increase from $30.7M to $108.4M, United States segment increase from $65.7M to $221.6M, Foreign segment increase from $6M to $17.7M. Higher net loss reflects General and administrative increase of 24% to $62.3M (expense).